Effect of risperidone on serum homocysteine levels in first-episode, drug-naïve patients with schizophrenia

Neuroscience Letters

Volumn 650, Issue , 2017, Pages 168-173

  Fan, Ning ^a   Tan, Yunlong ^a   Yang, Fude ^a   Tian, Li ^a,b   Chen, Song ^a   Li, Jia ^a   Wang, Zhiren ^a   Zhang, Xiangyang ^a,c  

^a BEIJING HUILONGGUAN HOSPITAL   (China)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotic; Drug na ve; Homocysteine; Schizophrenia

Indexed keywords

HOMOCYSTEINE; RISPERIDONE; BIOLOGICAL MARKER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIPSYCHOTIC AGENTS; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOMOCYSTEINE; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; RISPERIDONE; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85018955737     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2017.04.025     Document Type: Article

References (35)

1. [1] Uhlhaas, P.J., Singer, W., The development of neural synchrony and large-scale cortical networks during adolescence: relevance for the pathophysiology of schizophrenia and neurodevelopmental hypothesis. Schizophr. Bull. 37 (2011), 514–523.
2. [2] Fatemi, S.H., Folsom, T.D., The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 35 (2009), 528–548.
3. [3] Gruber, O., Santuccione, C.A., Aach, H., Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system. Front. Psychiatry, 5, 2014, 32.
4. [4] Insel, T.R., Rethinking schizophrenia. Nature 468 (2010), 187–193.
5. [5] Krebs, M.O., Bellon, A., Mainguy, G., Jay, T.M., Frieling, H., One-carbon metabolism and schizophrenia: current challenges and future directions. Trends Mol. Med. 15 (2009), 562–570.
6. [6] Feng, L.G., Song, Z.W., Xin, F., Hu, J., Association of plasma homocysteine and methylenetetrahydrofolate reductase C677T gene variant with schizophrenia: a Chinese Han population-based case-control study. Psychiatry Res. 168 (2009), 205–208.
7. [7] Haidemenos, A., Kontis, D., Gazi, A., Kallai, E., Allin, M., Lucia, B., Plasma homocysteine folate and B12 in chronic schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 31 (2007), 1289–1296.
8. [8] Nishi, A., Numata, S., Tajima, A., Kinoshita, M., Kikuchi, K., Shimodera, S., Tomotake, M., Ohi, K., Hashimoto, R., Imoto, I., Takeda, M., Ohmori, T., Meta-analyses of blood homocysteine levels for gender and genetic association studies of the MTHFR C677T polymorphism in schizophrenia. Schizophr. Bull. 40 (2014), 1154–1163.
9. [9] Ho, P.I., Ortiz, D., Rogers, E., Shea, T.B., Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J. Neurosci. Res. 70 (2002), 694–702.
10. [10] Kruman, I.I., Culmsee, C., Chan, S.L., Kruman, Y., Guo, Z.H., Penix, L.R., Mattson, M.P., Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci. 20 (2000), 6920–6926.
11. [11] Dietrich-Muszalska, A., Malinowska, J., Olas, B., Glowacki, R., Bald, E., Wachowicz, B., Rabe-Jablonska, J., The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients. Neurochem. Res. 37 (2012), 1057–1062.
12. [12] Wysokinski, A., Kloszewska, I., Homocysteine levels in patients with schizophrenia on clozapine monotherapy. Neurochem. Res. 38 (2013), 2056–2062.
13. [13] Ma, Y.Y., Shek, C.C., Wong, M.C., Yip, K.C., Ng, R.M., Nguyen, D.G., Poon, T.K., Homocysteine level in schizophrenia patients. Aust. N. Z. J. Psychiatry 43 (2009), 760–765.
14. [14] Brown, A., Bottiglieri, T., Schaefer, C., Quesenberry, C., Liu, L., Bresnahan, M., Susser, E., Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch. Gen. Psychiatry 64 (2007), 31–39.
15. [15] Lipton, S.A., Kim, W.K., Choi, Y.B., Kumar, S., D'emilia, D.M., Rayudu, P.V., Arnelle, D.R., Stamler, J.S., Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Neurobiology 94 (1997), 5923–5928.
16. [16] Kale, A., Naphade, N., Sapkale, S., Kamaraju, M., Pillai, A., Joshi, S., Mahadik, S., Reduced folic acid, vitamin B12 and docosahexaenoic acid and increased homocysteine and cortisol in never-medicated schizophrenia patients: implications for altered one-carbon metabolism. Psychiatry Res. 175 (2010), 47–53.
17. [17] Petronijevic, N.D., Radonjic, N.V., Ivkovic, M.D., Marinkovic, D., Piperski, V.D., Duricic, B.M., Paunovic, V.R., Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog. Neuro-psychopharmacol. Biol. Psychiatry 32 (2008), 1921–1926.
18. [18] Ellingrod, V.L., Miller, D.D., Taylor, S.F., Moline, J., Holman, T., Kerr, J., Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants. Schizophr. Res. 98 (2008), 47–54.
19. [19] Lajin, B., Alhaj Sakur, A., Michati, R., Alachkar, A., Association between MTHFR C677T and A1298C, and MTRR A66G polymorphisms and susceptibility to schizophrenia in a Syrian study cohort. Asian J. Psychiatry 5 (2012), 144–149.
20. [20] Mabrouk, H., Douki, W., Mechri, A., Younes, M.K., Omezzine, A., Bouslama, A., Gaha, L., Najjar, M.F., Hyperhomocysteinemia and schizophrenia: case control study. L'Encephale 37 (2011), 308–313.
21. [21] Tsuda, Y., Saruwatari, J., Yasui-Furukori, N., Meta-analysis: the effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open, 4, 2014, e004216.
22. [22] Verhoef, P., van Vliet, T., Olthof, M.R., Katan, M.B., A high-protein diet increases postprandial but not fasting plasma total homocysteine concentrations: a dietary controlled, crossover trial in healthy volunteers1. Am. J. Clin. Nutr. 82 (2005), 553–558.
23. [23] Manavifar, L., Nemati Karimooy, H., Jamali, J., Talebi Doluee, M., Shirdel, A., Nejat Shokohi, A., Fatemi Nayyeri, M., Homocysteine, cobalamin and folate status and their relations to neurocognitive and psychological markers in elderly in northeasten of Iran. Iran. J. Basic Med. Sci. 16 (2013), 772–780.
24. [24] Bicikova, M., Hampl, R., Hill, M., Ripova, D., Mohr, P., Putz, Z., Neuro- and immunomodulatory steroids and other biochemical markers in drug-naive schizophrenia patients and the effect of treatment with atypical antipsychotics. Neuro Endocrinol. Lett. 32 (2011), 141–147.
25. [25] Misiak, B., Frydecka, D., Slezak, R., Piotrowski, P., Kiejna, A., Elevated homocysteine level in first-episode schizophrenia patients-the relevance of family history of schizophrenia and lifetime diagnosis of cannabis abuse. Metab. Brain Dis. 29 (2014), 661–670.
26. [26] Kevere, L., Purvina, S., Bauze, D., Zeibarts, M., Andrezina, R., Rizevs, A., Jelisejevs, S., Piekuse, L., Kreile, M., Purvins, I., Elevated serum levels of homocysteine as an early prognostic factor of psychiatric disorders in children and adolescents. Schizophr. Res. Treat., 2012, 2012, 373261.
27. [27] Garcia-Miss Mdel, R., Perez-Mutul, J., Lopez-Canul, B., Solis-Rodriguez, F., Puga-Machado, L., Oxte-Cabrera, A., Gurubel-Maldonado, J., Arankowsky-Sandoval, G., Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J. Psychiatr. Res. 44 (2010), 441–446.
28. [28] Kahn, R.S., Sommer, I.E., The neurobiology and treatment of first-episode schizophrenia. Mol. Psychiatry 20 (2014), 84–97.
29. [29] Muntjewerff, J.W., van der Put, N., Eskes, T., Ellenbroek, B., Steegers, E., Blom, H., Zitman, F., Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Psychiatry Res. 121 (2003), 1–9.
30. [30] Hill, M., Shannahan, K., Jasinski, S., Macklin, E.A., Raeke, L., Roffman, J.L., Goff, D.C., Folate supplementation in schizophrenia: a possible role for MTHFR genotype. Schizophr. Res. 127 (2011), 41–45.
31. [31] Bhalodia, Y., Sheth, N., Vaghasiya, J., Jivani, N., Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury. Ren. Fail. 32 (2010), 1088–1094.
32. [32] Ntaios, G., Savopoulos, C., Chatzopoulos, S., Mikhailidis, D., Hatzitolios, A., Iatrogenic hyperhomocysteinemia in patients with metabolic syndrome: a systematic review and metaanalysis. Atherosclerosis 214 (2011), 11–19.
33. [33] Cheng, L.S., Prasad, A.N., Rieder, M.J., Relationship between antiepileptic drugs and biological markers affecting long-term cardiovascular function in children and adolescents. Can. J. Clin. Pharmacol. 17 (2010), e5–46.
34. [34] Kuzman, M.R., Müller, D.J., Association of the MTHFR gene with antipsychotic-induced metabolic abnormalities in patients with schizophrenia. Pharmacogenomics 13 (2012), 843–846.
35. [35] Girardi, P., Serafini, G., Pompili, M., Innamorati, M., Tatarelli, R., Baldessarini, R.J., Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Pharmacopsychiatry 43 (2010), 66–72.